Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
4.190
-3.510 (-45.58%)
Jun 30, 2026, 10:02 AM EDT - Market open
Unicycive Therapeutics Employees
As of December 31, 2025, Unicycive Therapeutics had 22 total employees, including 21 full-time and 1 part-time employees. The number of employees decreased by 1 or -4.35% compared to the previous year.
Employees
22
Change (1Y)
-1
Growth (1Y)
-4.35%
Revenue / Employee
n/a
Profits / Employee
-$1,813,091
Market Cap
111.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | -1 | -4.35% | 21 | 1 |
| Dec 31, 2024 | 23 | 9 | 64.29% | 22 | 1 |
| Dec 31, 2023 | 14 | 2 | 16.67% | 14 | 0 |
| Dec 31, 2022 | 12 | 3 | 33.33% | 12 | 0 |
| Dec 31, 2021 | 9 | 8 | 800.00% | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| MediWound | 121 |
| Arcturus Therapeutics Holdings | 111 |
| Compugen | 75 |
| Precision BioSciences | 66 |
| Korro Bio | 49 |
| NovaBridge Biosciences | 30 |
UNCY News
- 2 hours ago - Unicycive Therapeutics receives complete response letter from FDA for OLC NDA - TheFly
- 2 hours ago - Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA) - GlobeNewsWire
- 8 days ago - Unicycive Therapeutics Proxy statement: Proxy filing - Filings
- 24 days ago - Unicycive Therapeutics files $150M mixed securities shelf - TheFly
- 25 days ago - Unicycive Therapeutics Registration statement: Registration filing - Filings
- 26 days ago - Unicycive Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Unicycive Therapeutics price target raised to $18 from $15 at Benchmark - TheFly
- 4 weeks ago - Unicycive Therapeutics Earnings release - Filings